Nexalin Technology CEO Provides Letter to Shareholders - Seite 2

We also announced encouraging results from a recent clinical study of our Gen-2 tACS device for treating adult patients with chronic insomnia. The published results from this clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to patients treated with placebo. Data published in the Journal of Psychiatric Research suggests that the Gen-2 tACS device may have the potential to reduce chronic insomnia and consistently improve sleep quality in adults.

Additionally, the Nexalin clinical teams have published 6 additional clinical studies in recognized international peer-reviewed journals evaluating the safety, tolerability and efficacy of the new advanced 15 milliamp waveform. The data in these published studies, showing statistically significant improvements in key parameters (as compared to a placebo cohort), provide a basis for optimism that our devices could have applicability for multiple disciplines related to mental health.

Introducing the HALO Clarity & the Nexalin Virtual Clinic

Building on our strong clinical momentum, we recently unveiled the HALO Clarity (HALO), a headset powered by various processing systems and microprocessors to deliver a new Gen-3 waveform at 15 milliamps. Redesigned to incorporate Deep Intracranial Frequency Stimulation (DIFS), the HALO is a significant leap forward over prior versions of the device, in multiple respects, and will enable patients to receive treatment within the convenience and accessibility of our Virtual Clinic setting.

We believe that HALO, developed on an advanced technology platform, possesses the capability to penetrate structures deep in the mid-brain that are associated with mental health disorders. We believe that the innovative technique underlying the HALO architecture, and embedded in all of our next-generation devices, will generate enhanced patient therapeutic responses without adverse side effects. 

Our Virtual Clinic will allow patients to be treated by the HALO within the privacy of their own homes. The Virtual Clinic will afford remote access to our prescribing physicians so that they can seamlessly monitor patient data through a proprietary medical app, a cloud-based program providing secure, “over-the-air” electronic transmission of patient data.

The development of the Virtual Clinic is far along and is expected to support the monitoring and collection of HALO use data by medical professionals in a seamless manner resulting in an integrated workflow – from assessment, to authorization, to shipment – all under medical supervision.